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Analysis of head and neck 
carcinoma progression reveals 
novel and relevant stage-
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immortalisation and malignancy
Ratna Veeramachaneni ?, Thomas Walker   ?, Timothée Revil   ?, Antoine De Weck ?ǡ ? ?, 
Dunarel Badescu ?, James O’Sullivan ?, Catherine Higgins ?, Louise Elliott ?, 
ƤLiloglou   ?, Janet M. Risk   ?, Richard  ?ǡ ?, Lynne Hampson ?, 
Ian Hampson ?, Simon Dearden ?, Robert  ?, Stephen Prime ?, Keith Hunter ? ?, 
Eric Kenneth Parkinson ?, Jiannis Ragoussis ? & Nalin Thakker   ?ǡ ?
We report changes in the genomic landscape in the development of head and neck squamous cell 
carcinomas HNSCC from potentially premalignant lesions (PPOLS) to malignancy and lymph node 
metastases. Likely pathological mutations predominantly involved a relatively small set of genes 
reported previously ( ? ?,  ?,  ?,  ?,  ?	 ?) but also other predicted 
cancer drivers (
,  ?,  ? ?,  ? and 	 ?). Notably, all these mutations arise early and 
Ǥǡ
loss of senescence, are of consistent somatic copy number alterations (SCNAs) involving chromosomal 
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the evolution of SCNAs in HNSCC progression. One of the earliest SCNAs involved deletions of  ? 
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and occurred at high frequency in the immortal HNSCC cell lines. Modulation of  ? in cell lines 
Ƥ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Globally, head and neck carcinomas account for over 550,000 new cases per annum with a mortality of approx-
imately 275,000 cases per year1. By far, the commonest site of cancer within this region is the oral cavity and the 
commonest type of tumour is squamous cell carcinoma (SCC), which accounts for over 90% of all malignant 
tumours at this site. HNSCC is associated with high mortality having an overall 5-year survival rate of less than 
50%. Furthermore, both the disease and the multimodal treatments options involved are associated with high 
morbidity2.
he molecular pathology of head and neck squamous carcinoma has been extensively studied previously3 and 
the common somatic genetic changes have been characterised4–8. here have been some studies of the multistage 
evolution of these tumours9 but this is less well characterised. A small number of tumours arise from pre-existing 
lesions (known as potentially malignant lesions or PPOLs) such as leukoplakia or erythroplakia, which display 
variable epithelial dysplasia10. However, the vast majority are thought to arise de novo from macroscopically 
normal appearing mucosa or possibly undiagnosed PPOLs. Support for the latter comes from data showing that 
the transcriptional signatures of PPOLs are retained in unrelated samples of SCC both in vivo11 and in vitro12. 
Nevertheless, it is clear that tumours arise from within a wide ield bearing the relevant genetic alterations and 
that there is a risk of synchronous or metachronous tumours13,14. A fuller understanding of the events in evolu-
tion of these cancers may permit the development of biomarkers or efective therapeutic interventions possibly 
targeting not just tumours but also the early changes in the ield. he irst multi-step model proposed for carcino-
genesis in HNSCC15 suggested typical alterations associated with progression from normal mucosa to invasive 
carcinoma, with dysplasia relecting an earlier stage of cancer progression.
We, and others, have previously shown that both SCCs and PPOLs yield either mortal and immortal cells in 
vitro16,17 and sometimes, mixtures of the two16–18. he status of these mortal cells is unclear. Unlike the immor-
tal cells, they lack inactivation of TP53 and CDKNA, but our limited previous investigations show that they are 
genetically stable. Nevertheless, they oten have extended replicative lifespans16,17, possess neoplastic phenotypes, 
such as resistance to suspension-induced terminal diferentiation16 and have expression signatures which are dis-
tinct from both immortal cells and normal cells12. Furthermore, these characteristics are present in mortal cells 
from both PPOLs and SCCs12 suggesting the presence of distinct pathways for the development of mortal and 
immortal SCC. Our preliminary work established that the mortal PPOL were cytogenetically diploid and had low 
levels of LOH16 but the immortal PPOLs have never been subjected to extensive genomic analysis. In addition, 
whilst extensive genetic analysis of HNSCC has been carried out in recent years4–6,8, including the identiication 
of key driver mutations, the stages in the cancer progression, at which they occur and the resulting phenotypes are 
still unknown. here are numerous previous studies of PPOLs limited to determining the frequency of alterations 
in speciic gene or speciic genetic regions. Exceptions to this are the study by Bhattacharya and colleagues9 and 
Wood and colleagues19, which reported a comprehensive analysis of copy number variation in primary PPOLs 
and HNSCC although in the later study, the PPOL analyses was conined to metachronous lesions. A very recent 
study reported the status of SCNAs and common driver mutations in several keratinocyte cultures derived from 
metachronous normal and dysplastic lesions characterised for replicative lifespan20. Here we extend their indings 
by a combination of exome/targeted sequencing, methylation and SNP/CGH array analyses, using our unique 
panel of fully characterised mortal cultures and immortal cell lines derived from both PPOLS and HNSCC, to 
show that these genetic alterations are mostly associated with cellular immortalisation and increase with the 
stage of tumour progression in this class of SCC keratinocyte. he principal focus of this study is to characterise 
in detail changes in the evolution and progression of HNSCC rather than focussing on HNSCC as a group which 
have already been well characterised with respect to mutation and genomic landscapes. In doing so we identify 
common alterations of the candidate tumour suppressor gene CSMD1 not highlighted previously and provide 
preliminary evidence of its function. Furthermore, alterations of CSMD1 were common in PPOL cultures and 
therefore may be early events in SCC development.
Results
Genes target for mutations in HNSCC are altered early in cancer development. Several recent 
genomic sequencing studies have fully characterised mutations in HNSCC4–7. In order to map these previously 
identiied mutations to progression of HNSCC, a small previously well-characterised panel of samples consisting 
of 3 PPOL mortal cultures, 7 PPOL cell lines (from lesions known to have progressed as well as lesions that had 
not progressed) 1 mortal culture derived from HNSCC and 11 HNSCC cell lines17,21,22 were selected for exome-se-
quencing or targeted sequencing of the top 40 genes identiied as altered in these cancers4 using HaloPlex Target 
Enrichment System (Agilent, Santa Clara, CA, USA). he sample details are given in Supplementary Data S1.
For exome sequencing, approximately 6 gigabases of sequence mapped to the human genome with an 
average of 65.7% (Range 33.8% to 86.1%) of the targeted exome covered at twenty-fold or higher (shown in 
Supplementary Data S2). For HaloPlex sequencing, approximately 800 megabases of sequence mapped to the 
human genome with an average of 94.8% of the targeted exons covered at twenty-fold or higher (shown in 
Supplementary Data S3).
For calling and iltering pathological mutations, we used the strategy described in Material and Methods. he 
iltering of the sequence variants is shown in Supplementary Data 4. he iltering was stringent and therefore, it is 
possible that some genuine pathological mutations may have been excluded. However, the full dataset is available 
through Dryad Digitial Repository (https://doi.org/10.5061/dryad.314k5k5).
Given the small numbers of samples examined in our study, we further targeted our analyses to cancer drivers 
identiied by IntOGen (Release 2014.12) he HaloPlex sequencing panel included 8 of the 10 most frequently 
mutated HNSCC driver genes. Limiting analyses to known cancer drivers also efectively excluded possible false 
positives that can arise due to DNA replication timing and low transcriptional activity23. hus, our signiicant 
driver mutations (Fig. 1) mirror those identiied by Lawrence and colleagues, 201323 following correction for 
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these factors. he mutational landscape of PPOL and HNSCC is shown schematically in Fig. 1. Full list of variants 
is provided in Supplementary Data S5.
Mutations were rare in mortal cultures (Fig. 1). One missense variant each of TP53 and KMT2D were observed 
in 2 PPOL cultures and one high impact NOTCH1 mutation was observed in HNSCC culture BICR80.
As with previous studies4–7, the mutation analyses revealed a small set of genes (TP53, KMT2D CDKN2A, 
PIK3CA, NOTCH1, and FAT1) as the most common targets for likely deleterious sequence mutations in immortal 
PPOL and HNSCC cell lines (Fig. 1). Mutation of TP53 and CDKN2A as an early event in head and neck carcino-
genesis is well established17,24–26. In the present study, however, we demonstrate for the irst time that mutations of 
KMTD2, PIK3CA and NOTCH1 also occur early. Furthermore, except for NOTCH1, the mutations are not only 
present in progressing lesions (D19, D20, D35) but also in non-progressing lesions (D4, D34, D38). Relatively 
frequent mutations were also detected in several other IntOgen-deined cancer drivers such as MGA, PABPC3, 
NR4A2, NCOR1 and MACF1 (Fig. 1); of these PABPC3, NR4A2, NCOR1 and MACF1 are detected as mutational 
cancer drivers in head and neck cancer in IntOgen.
Somatic copy number changes in evolution of HNSCC. Somatic copy number alterations in 7 PPOL 
cell lines, 11 mortal cell cultures derived from PPOL and 28 HNSCC cell lines (detailed in Supplementary Datas S1 
and S6) were derived using array based technologies. he full dataset of Nexus Copy Number v5.1 (BioDiscovery, 
Inc., CA, USA) data are available at Dryad Digital Repository (https://doi.org/10.5061/dryad.314k5k5).
Mortal keratinocyte cultures derived from PPOL are genetically stable. Mortal cultures derived from PPOL were 
genetically stable, showed very few copy number changes and no signiicant diferences compared to matched 
ibroblasts. hese data that are consistent with their diploid chromosome complement and previous limited loss 
of heterozygosity analysis16 (Fig. 2a and Supplementary Data S7).
Progressive somatic copy number changes follow immortalisation and loss of senescence in evolution of 
HNSCC. Our previous studies show that all immortal PPOL cell lines show inactivation of TP53 and CDKNA16–18  
that confer immortality and loss of senescence. In this study, we show that these cell lines showed in addition, 
consistent focal and arm-wide SCNAs that deine some of the earliest changes in the development of HNSCC 
that follow immortalisation and loss of senescence (Fig. 2a). Overall, consistent with previous studies9,19, com-
pared to normal ibroblasts, there were signiicant (P < 0.05) losses on chromosome 3p, 8p and 9p and gain of 
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Figure 1. Mutation landscape plot of iltered variants present from exome and HaloPlex captures. On the 
let, the genes shown contain a distinct mutation in at least three samples, while for the plot on the right, the 
genes shown are the genes known to be HNSCC drivers according to IntOGen. he bar plot on the let of both 
mutational landscape plot shows the percentage of samples that contain a variant in the speciied genes, with 
HNSCC drivers highlighted in green (let) and genes present in the HaloPlex capture highlighted in yellow 
(right). he waterfall plot illustrates the single most damaging variant found per gene and per sample, with 
colors indicating mutation types. he order of the mutation type legend shows the priority of the mutation 
selected when a gene contains multiple variants. M-PPOL: mortal potentially premalignant lesion cultures; IM-
PPOL: immortal PPOL cell lines (progressive: P and non-progressive: NP); HNSCC: Head and neck squamous-
cell carcinoma cultures (mortal: M and immortal: IM).
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chromosome 20 (Fig. 2b). However, there was clear heterogeneity in the nature of the changes observed in the 7 
immortal PPOL samples (Fig. 2c) with some specimens showing more frequent changes than others. his enabled 
us to further delineate the changes in the earliest stages of the HNSCC development.
Meaningful testing for signiicant diferences between subsets of PPOLS was not possible due to the small 
sample size and thus, hierarchical clustering was used to group samples by SCNAs (Fig. 2c). he samples clustered 
into two main groups that suggested a correlation of genomic changes with grade of dysplasia with higher-grade 
dysplasias showing more changes than lower-grade dysplasias (Fig. 2c). Furthermore, three cell lines (D19, D20, 
Figure 2. Somatic copy number changes in evolution of HNSCC. (a) Density and frequency plots showing 
copy number gains (blue) and losses (red) in normal ibroblasts, mortal PPOLs (M-PPOL), immortal PPOLs 
(IM-PPOL) and HNSCC cell lines with and without lymph node metastases (LN + ve and LN − ve respectively). 
(b) Subtraction frequency plots showing diferences in copy number gains (blue) and losses (red) between 
(i) normal ibroblasts, and mortal PPOLs (M-PPOL), (ii) immortal PPOLs (IM-PPOL) and all HNSCC cell 
lines and (iii) HNSCC cell lines with and without lymph node metastases (LN + ve and LN − ve respectively). 
Both high and all copy number changes are shown for LN + ve and LN − ve HNSCC cell lines. Blue arrows on 
the right indicate lanes with regions of diference showing statistical signiicance (p < 0.05). (c) Density and 
frequency plots showing copy number gains (blue) and losses (red) in individual immortal PPOL cell lines 
showing hierarchical clustering and grade of dysplasia (CIS, carcinoma in-situ).
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D35) from PPOLs that progressed to carcinomas (progressive PPOLs or P-PPOL), clustered in a discrete sub-
group distinct from cell lines (D34, D4) derived from non-progressive lesions (N-PPOL). his was remarkably 
similar to the clustering previously observed for these cell lines by gene expression proiles12 indicating these 
signatures may at least in part relect the underlying somatic copy number changes.
P-PPOLs were characterised by consistent arm-level losses of chromosome arms 3p and 8p with homozygous 
deletions of FHIT (3p14.1) and CSMD1 (8p23.2) (shown in Supplementary Data S8). In addition, two of the 
three P-PPOLs (D19, D35) showed further arm-level SCNAs on several other chromosomes (+3q, +5p, +7p 
+8q, −13p, −13q, −18p −18q, +20, a pattern similar to HNSCC cell lines indicating a more advanced stage in 
progression.
he pattern of SCNAs in cell lines derived from lesions that had not progressed to date (NP-PPOLs, D34, D4, 
D9 and D38) relected their earlier stage of evolution (Fig. 2c). hese cells harboured focal SCNAs involving the 
CSMD1 (3 of 4 cell lines) and FHIT (2 of 4 cell lines) on chromosome 8p23.2 and 3p14.1 respectively, and showed 
arm-level gains of chromosome 20 (3 of 4 cell lines) together with variable and largely focal SCNA of several other 
chromosomal arms.
Progression to HNSCC was characterised by two main features: (i) an increased frequency of SCNAs and/or 
extension of SCNA regions involved in immortal PPOLs and (ii) involvement of further regions not involved in 
PPOLs (Fig. 2). hus, there were statistically signiicant increases in frequency of losses of proximal part of Chr3p, 
and Chr18q and gains of Chr20q. In addition to this, there were SCNAs involving new regions including loss of 
Chr4q and Chr10p together with gains of Chr5p, Chr9q, Chr14q and Chr11q. he overall changes in HNSCC cell 
lines were similar to those described for HPV–ve tumours in previous studies3–9.
Some genes (e.g., CDKN2A, CDKN2B) that showed homozygous deletions in PPOLs, showed an increase 
in frequency of the same in HNSCCs. here were in addition, homozygous deletions of further genes such as 
PTPRD, LRP1B and LINGO2, which showed frequent hemizygous deletions in the PPOL cell lines suggesting fur-
ther selection in progression to HNSCC. High copy number gains, largely absent in PPOLs, were more frequent 
and principally centred on chromosome 11q.
he aggregate HNSCC cell line data concealed diferences between cell lines from tumours with and without 
lymph nodal metastases (LN + ve and LN − ve respectively). Lymph node metastases status of 17 of 28 HNSCC 
lines was known (10 LN + ve; 7 LN − ve). he LN + ve cell lines showed higher frequency of high copy (>2) 
number gains of a 1.76 Mb region at chromosome 11q13.2-q13.3 (p < 0.05) that encompasses 10 genes including 
CCND1 and the microRNA hsa-miR-548k (Fig. 2a). Similarly, a higher frequency of high copy number gains 
on two regions on chromosome arm 3q was observed involving NAALADL2 (chromosome band 3q26.32), and 
TP63 and CLDN1 (chromosome band 3q28). Hierarchical clustering of all HNSCC cell lines by high-copy num-
ber aberrations also revealed two major groupings deined by the presence or absence of the high-copy number 
amplicon on chromosome band 11q13.2-q13.4 (p < 0.01, q bound <0.1) (shown in Supplementary Data S9). 
In the group lacking the amplicon, only 2 of 8 cell lines with known nodal staging, were derived from LN + ve 
cancers and each of these involved a single node less than 2 cm (TNM stage N1). By contrast, in the group with 
the amplicon, 7 of 9 cell lines were derived from LN + ve cancers and 4 of the 7 tumours were graded as TNM 
stage N2 or higher. hese results are consistent with the recent indings linking the 11q13.3 amplicon with poor 
survival in HNSCC patients27.
We used several approaches to identify genes that are potential or likely target of the SCNAs and these are 
detailed in Supplementary Datas 10–12. hese approaches identiied genes already known to be implicated in 
HNSCC as well promising candidates that merit further investigation.
	 ? ? are early targets in HNSCC. In the PPOLs, the most common target genes for SCNA 
included the FHIT, CSMD1, CDKN2A and CDKN2B as described above and these are observed in both pro-
gressing and non-progressing lines deining them as earliest deined changes along with inactivation of TP53. In 
addition, we identiied less frequent homozygous and hemizygous deletions of FAT1 (14% and 43% respectively, 
Supplementary Data S12). Although, loss-of-function mutations of FAT1 in HNSCC are reported in this study 
as well as previous studies4–6,8, identiication of homozygous deletions of FAT1 in PPOLs establish inactivation of 
FAT1 as an additional early change in HNSCC development.
he functional roles in carcinogenesis of genes that are target for these early changes, are generally well 
characterised except for CSMD1. Thus, we explored whether CSMD1 functions as a tumour suppressor in 
HNSCC. CSMD1 is deleted in many tumour types28 and also shows rare somatic mutations29. We observed both 
homozygous and hemizygous deletions of CSMD1 (5/28 and 21/28 respectively) in HNSCC cell lines (shown in 
Supplementary Data S13).
Only one immortal PPOL (D38) had sustained a potentially deleterious missense mutation (R3193K) in 
CSMD1 and no likely pathogenic mutations were observed in HNSCC. CSMD1 promoter methylation analyses 
by pyrosequencing revealed hypermethylation in 9 of 12 (75%) HNSCC cell lines with matching normal samples 
(and several other HNSCC cell lines without matching normal tissues) (Fig. 3a), 3 of 7 (~43%) PPOL cell lines 
(Fig. 3b), and 15 of 24 (~63%) primary HNSCCs (Fig. 3c). he highest level of promoter hypermethylation was 
seen in immortal HNSCC cell lines with either hemizygous deletions (BICR56, BICR22, BICR82, BICR10 and 
T4) or absence of deletions (BICR63, BICR68 and H314) (detailed in Supplementary Data S13), and in the only 
immortal PPOL cell line (D9) that lacked CSMD1 deletions (Fig. 3, and Supplementary Data S8). Additionally, 
the frequency of promoter methylation in primary tumours (~63%) was not too dissimilar to the frequency 
of hemizygous deletions (~75%) in our HNSCC cell lines. hese indings suggest that frequent inactivation of 
CSMD1 in HNSCC occurs by deletion and/or promoter hypermethylation.
Stable transfection of full-length CSMD1 cDNA into the H103 cell line, which lacks endogenous expression of 
CSMD1 expression, resulted in a signiicant inhibition of proliferation (p = 0.0053) and invasion (p = 5.98 × 10−5 
- Matrigel in vitro assay). Results from a representative clone are shown in Fig. 4 (with data from all clones shown 
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in Fig. S9). CSMD1 expression was also silenced by stable transfection with an shRNA vector in the BICR16 cell 
line, which has a very low but detectable level of endogenous CSMD1 expression. his cell line has complete 
hemizygous deletion of the CSMD1 together with several regions of small homozygous deletions (detailed in 
Supplementary Data S13) although the functional state of the protein is unknown. he stable CSMD1-silenced 
clones showed a more variable efect on both proliferation and invasion; clones displayed a signiicant increase in 
invasion compared to parent cells (p = 1.82 × 10−5) but loss of CSMD1 did not have a signiicant efect on the rate 
of proliferation (p = 0.239). Data from representative clones are shown in Fig. 4 (with data from all clones show 
in Supplementary Data S14). It is possible that the inconsistent proliferation results with gene silencing are due to 
the fact that these cell lines have acquired the necessary cancer traits with some CSMD1 expression and that these 
traits are not signiicantly impacted by additional knockdown of residual and possibly hypofunctional CSMD1. 
Overall, however, these data support a role for CSMD1 as a tumour suppressor gene inactivated in the very early 
stages of HNSCC development.
Homozygous deletions of other genes (NCKAP5, SORBS2, CCSER1) not previously implicated in HNSCC 
were also identiied in GISTIC peak regions in PPOLs. NCKAP5 was excluded as a likely common target by fur-
ther analyses (detailed in Supplementary Data S15) but the other genes remain to be characterised.
Identiication of key genes in progression from PPOLs to HNSCC by integrative analyses. Gene expression array 
data were available for 29 samples12. We used integrative analyses to further delineate key genes in transition from 
Figure 3. Clustered column chart representing pyrosequencing analyses of the CSMD1 promoter region. 
Sample ID is shown on the X-axis and mean methylation percentage is represented on the Y-axis. For each 
sample, a mean methylation percentage greater than 5% was considered as signiicant promoter methylation. 
(a) Mortal and immortal HNSCC cell lines. Signiicant promoter methylation was observed in12 of 17 (~70%) 
immortal HNSCC cell lines but not in any of the mortal HNSCC cell lines (indicated by *). he highest levels of 
promoter methylation were in cell lines with hemizygous deletions (BICR56, BICR22, BICR82, BICR10 and T4) 
or no deletions (BICR63, BICR68 and H314). (b) PPOL cell lines/cultures. Signiicant promoter methylation 
was observed 3 of 7 (~43%) immortal PPOL lines but not in any of the mortal PPOL cultures (indicated by *).  
he highest level of promoter methylation was in a single immortal cell line (D9) that had no deletions at the 
CSMD1 locus. (c) Primary HNSCCs and matching normal tissues. Signiicant promoter methylation was 
observed in 15 of 24 (approximately 63%) cases.
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PPOLS to HNSCC. We identiied genes that showed signiicant correlation of copy number with gene expres-
sion, from genomic regions that showed statistically signiicant diference in frequency of SCNA/LOH between 
PPOLs and HNSCC cell lines (detailed in Supplementary Data S16). his identiied 67 genes (Fig. 5) of which 
50 have been previously reported to be show some association with cancer (including NOTCH1 and PIK3CA) 
using PUBMED search. Nine of the 50 genes have been previously associated with HNSCC including DVL3, and 
5 genes (NOTCH1, PPP6C, RAC1, EIF4G1, PIK3CA) were identiied as mutational cancer drivers in IntOGen 
(Release 2014.12).
Surprisingly, many genes in GISTIC regions that showed high frequency of SCNAs in HNSCC including 
known HNSCC cancer drivers did not show correlation with gene expression. A priori it may be expected that 
Figure 4. Phenotypic efects of CSMD1 expression modulation in HNSCC. Let panel: forced CSMD1 
expression in the CSMD1 non-expressing H103 cell line. Right panel: silencing of CSMD1 in the CSMD1-
expressing BICR16 cell line. (A) CSMD1 mRNA transcript quantiication by RT-qPCR and protein 
quantiication by low cytometry for generated clones, presented as fold change normalised to the reference 
cell line. Let: H103 CSMD1-expressing clones and H103 CSMD1-negative parent cells and CSMD1-disrupted 
clone H103-mcl-21, normalised to SCC116 CSMD1 expressing cells (red outline). Right: BICR16 CSMD1-
silenced clones normalised to CSMD1-expressing BICR16 parent cell line. Boxplots represent RQ normalised 
to reference cells. Each box plot is the relative quantiication (RQ) of two plates each of triplicate target and 
reference gene CT values plus and minus log-transformed standard deviations and so incorporates intra-plate 
variance. Standard boxes depict the irst-third quartiles, whiskers depict ±1.5IQR with median values indicated 
below. Bar charts represent CSMD1 protein fold change normalised to reference cells. Error bars are ±standard 
deviation. (B) Efects of modulation of CSMD1 expression on cell proliferation. Let: CSMD1-expressing 
H103 monoclones compared to CSMD1-negative H103 parent and control cells. CSMD1 expression resulted 
in a reduced growth rate compared to CSMD1-negative parent and H103-mcl-21 cells (p = 0.0053). Right: 
Cell proliferation of CSMD1-silenced BICR16 clones compared to CSMD1-expressing BICR16 parent cells. 
CSMD1 silencing did not result in a signiicant change in growth rate compared to CSMD1-expressing parent 
cells (p = 0.239). Plots represent triplicate points from duplicate 96AQ assays for 96 hours with growth rates 
normalised to achieve relative fold change values for 0–72 hrs. Error bars are ±1 SD. (C) Efects of modulation 
of CSMD1 expression on gel invasion. hree trans-well chambers of 2 representative clones and parent cells 
are displayed (for full dataset see Supplementary Data 14). he invasion index of generated clones vs. parent is 
depicted as bar charts (white and black bars respectively). Let: CSMD1-expressing clones vs. CSMD1-negative 
H103 parent cells. CSMD1 expression results in a marked decrease of gel invasion (p = 5.975 × 10−5). Right: 
CSMD1-silenced clones vs. CSMD1-expressing BICR16 parent cells. CSMD1 silencing results in a marked 
increase in gel invasion (p = 1.822 × 10−05).
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Figure 5. Frequency of SCNA of genes from chromosomal regions that show a signiicant diference in 
SCNAs between PPOLs and HNSCC and correlation with expression. (a) Copy number gains. (b) Copy 
number losses. Genes reported to be associated with any cancer previously by PUBMED search (‘Gene name, 
Cancer’). **Genes reported to be associated with HNSCC previously by PUBMED search (‘Gene name, 
HNSCC’, oral cancer). Chromosomal regions showing diferences between PPOLS and HNSCC are indicated 
by letters on the let; in top panel (a), the regions are: A, chr3:151842842–152984767; B, chr3:157160169–
158933894; C, chr3:160599782–161161335; D, chr3:161705726–162566403; E, chr3:170691970–173911476; 
F, chr3:177707736–180451354; G, chr3:185035692–185529164; H, chr3:198578155–199298372; I, 
chr7:1631815–7317208; J, chr9:85367221–85868737; K, chr9:97596715–98774190; L, chr9:99427940–
100373274; M, chr9:101504820–101852863; N, chr9:123376788–125083831; O, chr9:126825879–127177239; 
P, chr9:129518474–129927677; Q, chr9:132985780–136636113; R, chr9:137291321–139534231; S, 
Chr14:62865875–63862093; T, chr3:186575268–187080482. In bottom panel (b), the regions are: A, 
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expression of tumour suppressor genes is less likely to show correlation with SCNAs as there are multiple ways 
of sustaining loss-of-function whilst gain-of-function changes are more limited and oten through copy number 
gains. However, oncogenes such as MYC also failed to show correlation. We tested whether integrative analysis 
was a reliable method to predict in vivo protein expression by analyses of two genes (BCL2L1 encoding an apop-
tosis regulator and CLDN1 encoding a component of tight junctions in epithelia) that showed a high frequency 
of copy number gains in HNSCC but were discordant with respect to correlation of copy number with gene 
expression in this study. Both CLDN1 and BCL2L1 showed signiicantly increased expression (p < 0.0001) by 
immunohistochemistry in HNSCC compared to normal tissues and PPOL (shown in Supplementary Data S17) 
indicating that correlation of SCNA with transcript expression in integrative analyses may not be a reliable surro-
gate indicator of functional importance of a gene.
Peak regions of SCNA in PPOLs and HNSCCs show signiicant progressive enrichment of genes involved in cancer 
pathways. As a further means for systematically identifying relevant genes in the GISTIC regions and the bio-
logical pathways involved in HNSCC evolution, we looked for enrichment of genes in relevant KEGG pathways 
in the GISTIC peak regions.
Signiicant (adj. P < 0.01) enrichment of genes in KEGG ‘pathways in cancer’ as well as other speciic cancer 
pathways was observed in both PPOLs and HNSCC cell lines (this is shown schematically in Fig. 6 and detailed in 
Supplementary Data S18). he enrichment was observed even if the analysis was limited to 1466 genes in GISTIC 
regions that showed signiicant correlation with expression ater correction for multiple testing (adj. p < 0.05) in 
immortal PPOL and HNSCC cell lines for which expression data was available.
he increase in both the size and the number of the SCNA regions in HNSCC compared to PPOLs, and the 
diferences in SCNAs between LN + ve and LN − ve HNSCC cell lines, were relected in the progressive increase 
and/or diferences in the enrichment for relevant KEGG pathways genes (Fig. 6). Some of the pathways identiied 
such as TP53 signalling and the cell cycle and genes therein, have been well characterised in HNSCC. However, 
other pathways such as ubiquitin–proteosome pathway and/or many of the genes within these pathways have not 
been implicated in HNSCC previously.
Similarly, the pathway analyses identiied many of the genes already known to be implicated in HNSCC 
conirming the utility of this approach. Signiicantly, in addition, this allowed identiication of many additional 
cancer-relevant genes (e.g., RHOA, PDL1, E2F1) from regions of frequent SCNA (Figs 7 and 8 and further path-
ways shown in Supplementary Data S19).
he examination in our cell line panel, of the frequencies of SCNAs involving genes in individual pathways, 
allowed us to map multiple pathway changes to stages in HNSCC progression (Fig. 8 and further pathways shown 
in Supplementary Data S19). For example, enrichment in SCNAs of genes in the NOTCH1 pathway was observed 
in both LN − ve and LN + ve cell lines (Fig. 8). However, there were diferences in the frequencies of SCNAs of 
the individual genes in the pathway suggesting diferent alterations of the pathway. LN + ve cell lines showed 
almost universal ampliication of HES1 and DVL3 and universal loss of KAT2B. LN + ve cell lines also showed 
a relatively low frequency (20%) of high and low copy number gains of NOTCH1. Gain of DVL3 and loss of 
KAT2B together with a relatively high frequency of gain of NUMB and loss of MAML2 may be expected to dis-
rupt NOTCH1 signalling but high frequency gains of the downstream targets HES1 and HEY1 may negate these 
changes or alternatively suggest complex ampliication and inhibition of subsets of NOTCH signalling elements. 
Clearly, these genes act in multiple pathways and it is diicult to determine the efect of gain or loss of any single 
gene without functional analyses. hus, copy number gains of DVL3 may be of signiicance in WNT signalling 
pathway or in the cross-talk between the two pathways. Ampliication of HES1 and DVL3 and loss of KAT2B were 
also observed in LN − ve cell lines as well as PPOLs albeit at a lower frequency. Instead, the LN − ve cell lines 
were characterised by a high frequency, low copy number gains of NOTCH1 and LFNG. In our small sample set, 
cell lines with mutations and ampliications of the NOTCH1 locus were mutually exclusive. Some genes such as 
MAML1 and MAML2 showed both copy number gains and losses possibly indicating further heterogeneity in 
NOTCH pathway aberration.
Discussion
Many recent studies have reported genetic and epigenetic changes in HNSCC4–8. Here, we have focussed on 
mapping the genetic changes to the stages of evolution of HNSCCs from the earliest stages to transition to malig-
nancy and progression to metastases. Given this focus and the need for well-characterised panel of cell lines 
from premalignant lesions and HNSCCs with and without lymph node metastases, the sample size is necessarily 
small. hus, the prevalence of the changes observed in this study must be regarded with caution. In addition, the 
changes observed in cell lines may not be fully representative of primary tumour because of clonal selection and 
continuing evolution in culture. However, the patterns of changes observed in our study are consistent with pre-
vious studies of primary HNSCC tumours3–9. Our indings are also consistent with indings of Beroukhim et al.28  
study of 3131 primary tumours of diferent sites. One major advantage of using cell lines is that extensive hetero-
geneity of primary tumour samples can mask SCNAs30,31, whereas cell lines give a cleaner results32.
Given the relatively low frequency (~30% or less) of sequence mutations of genes other than TP53 both in 
the current and previous studies, together with prevalence of consistent and frequent SCNA changes across wide 
range of tumours28, it is likely that the selection processes in the clonal evolution of these tumours is driven by 
chr3:57677987–58154068; B, chr3:61422777–73764765: C, chr3:87035206–88461236; D, Chr3:78706269–
79206160; E, chr10:16585949–17022250; F, chr10:26833288–28028304; G, chr3:161705726–162566403; 
chr17:8028078–9207567. he regions are ranked A onwards in order of decreasing statistical signiicance.
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these SCNAs. Additionally, we show here that the earliest changes are oten characterised by focal SCNAs (for 
example, deletions at chromosome 8p23 involving CSMD1) with further selection for loss of whole arm or large 
region of arm during progression or evolution. his suggests that regions of SCNAs harbour multiple genes that 
collectively provide selective growth advantage. his is supported by demonstration of enrichment of genes in the 
cancer relevant pathways in regions of peak SCNAs identiied in HNSCC. Several of these genes have previously 
individually been associated with HNSCC but the present study is the irst to systematically identify these genes 
and others, in the context of cancer-relevant pathways and map them to cancer progression.
In the present study, we conirm previous observations17,24–26, that loss-of-function of TP53 (primarily through 
sequence mutations) and CDKN2A (through SCNA, promoter hypermethylation and sequence mutations) are 
the earliest changes in HNSCC development. Furthermore, we demonstrate for the irst time that deleterious 
sequence mutations in previously identiied HNSCC cancer drivers KMT2D, PIK3CA, and NOTCH1, are also 
present in PPOLs and represent early but less common changes. Our study also provides indication that other 
genes such as MGA, PABPC3, NR4A2, NCOR1 and MACF1 are targets for deleterious mutations early in HNSCC 
progression. We provide evidence that inactivation of CSMD1 occurs very early in HNSCC and provide func-
tional evidence to support a tumour suppressor role. his is consistent with indings in breast cancer33. CSMD1 
encodes for a predicted transmembrane protein with a multidomain extracellular structure that is likely to act as a 
multi-ligand receptor mediating endocytosis of ligands. However, this remains to be characterised. One previous 
study has suggested a role for CSMD1 in reducing proliferation and invasive potential possibly through SMAD 
Figure 6. Enrichment of genes in cancer–relevant pathways in GISTIC extended regions in PPOLs and 
HNSCCs. Statistically signiicant enrichment (adjusted P < 0.01) for speciic pathways is indicated by a red 
box and lack of enrichment by a green box. he data are shown in detail in Supplementary Data 18. he ranges 
for adjusted P values corrected for multiple testing were: ‘All HNSCC’, 1.97E-12-0.0098; ‘LN + ve HNSCC’, 
5.76E-14-0.0083; ‘LN − ve HNSCC’, 7.52E-06-0.0074; PPOL, 5.34E-09-0.0007. In each section, the pathways 
were ranked from top to bottom in order of level of signiicance in the ‘All HNSCC’ group with highest level of 
signiicance at the top.
1 1SCIENTIFIC REPORTS |         (2019) 9:11992  | ǣȀȀǤȀ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
www.nature.com/scientificreportswww.nature.com/scientificreports/
pathway34. Whilst we did not detect mutations in FAT1 (a gene known to be mutated in HNSCC) in PPOL, we 
did identify hemizygous and homozygous deletions of the gene conirming that this gene is also an early target for 
inactivation in HNSCC development.
In contrast to study by Bhattacharya and colleagues9, this study did not ind evidence of signiicant subset of 
immortal PPOLs or HNSCCs that didn’t show loss at 8pter-p23.1 together with gains on 3q24-qter, 8q12-q24.2, 
and chromosome 20. However, our sample size is relatively small and there may be a selection in culture of the 
cells with these genetic alterations. Interestingly, in the previous study9 the subgroup lacking these genetic alter-
ations showed genetic stability, lack of TP53 mutations and a much-reduced predisposition to metastasis. It is 
Figure 7. Frequency of SCNAs of genes involved in KEGG ‘All pathways in cancer’ pathways that are 
signiicantly enriched in the GISTIC regions in PPOLs and HNSCC. Copy number gains (top panel) and copy 
number losses (bottom panel) in PPOLs, all HNSCC, and HNSCCs with and without nodal metastases (LN + ve 
and LN − ve respectively). **Genes showing signiicant correlation with expression in integrative analyses 
ater correction for multiple testing (adj. p < 0.05). *Genes showing nominal signiicance (p < 0.05) only are 
indicated by a single asterisk. Only genes showing at least 40% frequency of SCNA in at least one subgroup, are 
shown.
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interesting to speculate whether these correspond to ‘mortal’ PPOLs and HNSCC cultures, which are genetically 
stable and also lack TP53 mutations.
We were able to demonstrate signiicant diferences between LN + ve and LN − ve HNSCC cell lines particu-
larly with respect to a higher frequency of high copy gains on chromosome arm 11q centred around CCND1 and 
mir-548k, and chromosome arm 3q centred on TP63.
Our indings with respect to mutations and SCNA are similar but not identical to those reported by Wood 
and colleagues19 in synchronous dysplasia and HNSCC. In our study, we were able to show progressive changes 
with transformation to malignancy and lymphovascular spread. We note that in their study only a minority of 
low-grade dysplasias showed changes that were present in high-grade dysplasia and HNSCC, and they suggested 
that SCNAs were not necessary for the low-grade dysplasias to develop. We interpret this with some caution as 
unsurprisingly, low-grade dysplasia can be very di cult to distinguish from normal tissues with absolute certainty 
and agreement between histopathologists is generally weak in grading low-grade dysplasia. hus, some low-grade 
dysplasia lesions may represent genuine dysplasia whilst others may represent normal tissues. Regardless of this, 
what is clear from our study is that the SCNAs arise ater the breakdown of cellular senescence. he mortal PPOLs 
Figure 8. Frequency of SCNAs of genes involved in KEGG NOTCH signalling pathway that are signiicantly 
enriched in the GISTIC regions in PPOLs and HNSCC. Copy number gains (top panel) and copy number losses 
(bottom panel) in PPOLs, all HNSCC, and HNSCCs with and without nodal metastases (LN + ve and LN − ve 
respectively). **Genes showing signiicant correlation with expression in integrative analyses ater correction 
for multiple testing (adj. p < 0.05). *Genes showing nominal signiicance (p < 0.05) only are indicated by a 
single asterisk. Only genes showing at least 40% frequency of SCNA in at least one subgroup, are shown.
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do not display SCNAs. Additionally, the loss of expression of CDKN2A is nearly ubiquitous in our PPOL panel17 
and in PPOL tissues in vivo12,25,35.
NOTCH1 mutations4,5 and NOTCH1 pathway alterations have been reported in HNSCC6. We have extended 
these indings and demonstrate that NOTCH1 mutations are present in one of the three progressive PPOLs but 
not in any of the non-progressive lesions. his indicates that NOTCH1 inactivation is a relatively early event but 
still consistent with previous observations that suggest that NOTCH1 inactivation plays a key role in progression 
to invasive carcinoma of already initiated cells36. Our data are also consistent with that of Agrawal and colleagues5 
who have shown no association or mutual exclusivity of NOTCH1 and TP53 mutations. Interestingly, the results 
of the present study demonstrate that SCNAs of several genes in the NOTCH1 signalling pathway including 
NOTCH1, are more frequent then loss-of-function mutations of NOTCH1. Furthermore, many (but not all) of 
these SCNAs are gain of function changes in the NOTCH1 pathway. his is consistent with recent observations 
in primary HNSCC demonstrating over-expression of both ligands and receptors in this pathway37,38. Although 
mainly loss-of-function mutations in NOTCH1 have been reported in HNSCC to date, activating mutations in 
HNSCC in a Chinese population have also been described recently39. Our data support the suggested dual onco-
genic and tumour suppressive role for NOTCH1 in HNSCC. However, further functional analyses are necessary 
to conirm this. Additionally, the recent inding of a higher frequency of NOTCH1 mutations in aged oesophageal 
mucosa compared to tumours, raises the possibility that NOTCH1 mutations do not play a signiicant role in 
HNSCC40. Some SCNA’s of NOTCH1 pathway genes such as copy number gains of DVL3 may also be signiicant 
in the context of cross-talk with the WNT signalling pathway.
In this study, we identiied a potentially deleterious NOTCH1 variant in one mortal HNSCC lines. If the muta-
tion in the mortal line which has a wild type p5336 and no detectable CNVs (this study) or LOH16 is pathological 
as predicted, it would suggest that NOTCH1 mutations are independent of genomic instability and consistent 
with the recent inding of frequent deleterious NOTCH1 mutations in aged oesophageal mucosa40.
he presence of NOTCH1 mutations in this line also ofers a plausible explanation for the poor diferentiation 
of this line in both suspension16,41 and surface culture16 and is also consistent with recent data showing that the 
knockdown of NOTCH1 expression in human keratinocytes recreates a poorly diferentiated epithelium reminis-
cent of dysplasia42. Furthermore, NOTCH1 has been shown to mediate keratinocyte stratiication41,43 and stem 
cell maintenance44. However, NOTCH1 deletion has also been shown to promote tumourigenesis and tumour 
progression through paracrine efects45, the former of which would also be consistent with NOTCH1 mutations 
in PPOLs. Moreover, this last observation would be consistent with the reports of NOTCH2 and NOTCH3 muta-
tions in human SCC4 because loss-of-function of these paralogues promotes tumourigenesis in mouse skin in a 
paracrine fashion but does not replicate the efect of NOTCH1 deletion on keratinocyte diferentiation45. It has 
also been reported that NOTCH1 is a TP53 target gene41 and as most of the immortal PPOL and HNSCC lines 
have TP53 mutations this could be an additional mechanism of its inactivation and is consistent with the altered 
regulation of hairy enhancer of split 2 (HES2) in these lines12,41.
In conclusion, we have further characterised speciic genetic changes that mark progression in head and neck 
squamous cell carcinogenesis. Although genomic landscapes and progression models of SCCHN4–7,15 have been 
published previously, we have been able to use our well characterised cell line panels to tentatively assign genetic 
changes, including novel ones, to speciic stages of progression in transcriptionally distinct mortal and immortal 
classes10,12 of the disease and also to cell function. he indings of this study, in addition to adding to our knowl-
edge of potential druggable alterations in HNSCC, increase the understanding of early stages of HNSCC evolu-
tion, which may contribute to better control of premalignancy and prevention of progression to frank malignancy.
Materials and Methods
Samples. All methods were carried out in accordance with relevant guidelines and regulations. he use of 
patient samples in parts of this study was approved by the UK National Research Ethics Service (REF No: 08/
H1006/21 and EC.47.01). Primary tumour samples were collected with full informed consent under research 
ethics approval EC.47.01. Anonymised archival samples used in immunohistochemistry analyses were used with 
consent exemption granted by research committee approval 08/H1006/21 under the UK Human Tissues Act 
2004.
Details of the samples are shown in Supplementary Data 1. For SNP array, the sample set consisted of 16 
HNSCC cell lines, 7 PPOL cell lines and 11 mortal cell cultures derived from PPOL. DNA from matching ibro-
blasts was available for 6 HNSCC cell lines, 1 immortal PPOL cell line and 2 mortal PPOL cultures. he sample 
culture conditions were as described previously16 and DNA was prepared from cell lines using standard protocols. 
he sample set for array CGH consisted of 12 HNSCC cell lines.
SNP array analyses. SNP genotyping of the primary HNSCC panel was performed using the Illumina 
HumanHap550 Genotyping Beadchip and Ininium Assay II as per standard protocols. DNA from the cell lines 
was quantitated with NanoDrop (hermo Scientiic) and 750 ng was used per assay.
Array CGH. ArrayCGH data were kindly provided by Dr Simon Deardon, AstraZeneca, UK.
Data analyses. he average genotype call rate was 98.25%; genotype data from two samples with a call 
rate of <95% in BeadStudio v3.1 (Illumina) were excluded from analyses. Over 75% of samples had GenTrain 
score (measure of reliability based on the total array of calls for a given SNP) of ≥0.7 and none were below 0.4. 
Data were pre-processed in GenomeStudio v2009.1 (Illumina) and imported into Nexus Copy Number v5.1 
(BioDiscovery, Inc., CA, USA) and OncoSNP v2.746 for further analyses. ArrayCGH data from a second HNSCC 
panel were also imported into Nexus Copy Number v7.5 (BioDiscovery, Inc., CA, USA).
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he robust variance sample QC calculation (a measure of probe to probe variance ater major outliers due to 
copy number breakpoints are removed from the calculation) in Nexus Copy Number v7.5 (BioDiscovery, Inc.), 
was used to assess the quality of the samples. Data for samples with a score >0.2 were excluded and the score for 
the remaining samples was in the range 0.03–0.20. For identiication of copy number and copy neutral changes, 
the BioDiscovery’s SNPRank Segmentation Algorithm was used with signiicance level of 1 × 10−6 and a min-
imum number of probes per segment of 5. hresholds for determining copy number variation were set at −1 
for homozygous deletion, −0.18 for hemizygous deletion, 0.18 for gain (single copy gain) and 0.6 for high gain 
(2 or more copies). An area was considered to be showing LOH if 95% of the probes in the region had a B allele 
frequency of >0.8 or <0.2 (homozygous frequency and value thresholds of 0.95 and 0.8 respectively). Allelic 
imbalance was deined as 95% of the probes in the region showing a B allele frequency of between 0.2 and 0.4 or 
0.6 and 0.8 (i.e. heterozygous imbalance threshold of 0.4).
Areas of the genome with a statistically high frequency of aberration (Q-bound value <=0.5–0.25 and 
G-score cut-of <=1) ater correction for multiple testing using FDR correction (Benjamini & Hochberg), were 
identiied using the GISTIC (Genomic Identiication of Signiicant Targets in Cancer) approach47.
Group comparisons were made in Nexus with diferences in frequency of speciic events at any chromosomal 
location tested for signiicance by two-tailed Fisher’s Exact Probability Test with an accepted signiicance level of 
p < 0.01 at a deined level of percentage diference. More stringent Q-bound values based on two-tailed Fisher’s 
Exact Probability Test corrected for multiple testing using Benjamini-Hochberg FDR correction (Benjamini & 
Hochberg) as well as a minimum of set percent diference in frequencies between the two groups; signiicance 
was accepted at <0.25.
Promoter methylation analyses. Genomic DNA (approximately 1 mg each) from all the HNSCC and 
PPOL cell lines and matched primary HNSCC samples used were subjected to bisulite treatment using the 
EZ DNA methylationTM kit (Zymo Research, USA) according to the manufacturer’s protocol. 30 ng each of the 
bisulite-treated DNA was used for the pyrosequencing reaction.
PCR and sequencing primers for the pyrosequencing methylation analyses of the CpG rich promoter region 
were designed using the pyro-Q-CpG sotware for CSMD1. he forward primer was biotinylated and was used in 
low concentration (5 pmol) along with ampliication cycles of 45 to exhaust the primers. he forward and reverse 
primer sequences used in the study were CSMD1-F-5′gtagttttagatagatagagtttagttt3′, R-5′acaaatctcctttctcca3′ 
with its sequencing primer 5′ aaatctcctttctccaacct3′. Optimized annealing temperature for CSMD1 PCR primer 
pairs is 54 °C. Using bisulite-treated DNA as a template, regions of interest were ampliied by standard PCR 
cycling conditions in a 96-well plate using Qiagen’s Hot start Taq Polymerase to avoid nonspeciic ampliication. 
he speciicity of the PCR products was then veriied by agarose gel electrophoresis. For the pyrosequencing 
reaction, the PCR product was made single stranded by immobilizing the incorporated biotinylated primer on 
streptavidin-coated beads. he sequence run and analysis were done on the PyroMark™Q96 MD pyrosequencer 
(Qiagen) according to the manufacturer’s instructions. he sequence runs were analysed using the Pyro Q-CpG 
sotware. he peak heights observed represented the quantitative proportion of the alleles. he sotware generated 
methylation values for each CpG site and also the mean methylation percentage for all the CpG sites analyzed.
Generation of stable  ?ǦǤ A panel of nine OSCC cell lines was pro-
iled for CSMD1 transcript and protein expression status (data not shown). his identiied the CSMD1-expressing 
cell line BICR16 and the CSMD1 non-expressing cell line H103.
BICR16 cells were used to generate stable CSMD1-silenced monoclone and polyclone lines with HuSH 29mer 
pRS shRNA (Origene, Rockville, MD, USA). he degree of silenced CSMD1 expression level was conirmed by 
RT-qPCR and low cytometry assays. Primer sensitivity assays determined the limit of CSMD1 transcript detec-
tion at ive ORF copies per light-cycler well.
Stable forced CSMD1-expressing monoclone cells were generated by transfection of 15.5 kb pCMV6-CSMD1 
expression plasmid (Origene, Rockville, MD, USA) into the CSMD1-deleted cell line H103. he plasmid was lin-
earized at the SexAI restriction site within a predetermined 14% non-essential region and used to generate seven 
CSMD1-expressing monoclone cell lines using standard methods. he degree of forced CSMD1 expression was 
conirmed by RT-qPCR and low cytometry assays.
Cell proliferation was determined with CellTiter 96® Aqueous Cell Proliferation MTS Assay (Promega, 
Southampton, UK) as per the manufacturer’s protocols. Cell growth was calculated as a percentage growth change 
from the 24-hour time point and population-doubling times were determined. Gel-invasion was assayed using 
trans-well BD Bio-coat Matrigel Invasion Chambers and control wells (BD Biosciences, Oxford) as per manufac-
turer’s protocols. Optimal seeding densities were determined empirically. Triplicate Matrigel invasion chambers 
were used for each clone from a minimum of two diferent Matrigel batches. hree ields of view were cap-
tured for each Matrigel or control chamber (outer, middle, centre areas, each at 120° rotation from one another). 
Percentage invasion was calculated for each clone and expressed as an invasion index (ratio of clone to parent 
percentage invasion). Statistical analysis was performed in IBM SPSS 20 & 22 (Wilcoxon Sign-Rank Test) with 
alpha levels set at 0.05.
Integrative analysis. Before correlating the SCNA and gene expression values corrections were applied for 
polyploidy and heterogeneity.
When considered a by-product of instability rather than a response of biological signiicance, the copy number 
(CN) values were altered to remove the ubiquitous chromosomal ampliication observed in polyploid samples. To 
do so, all the CN values inferred for SNPs in chromosome arms with mean CN larger than 2.5 were reduced by 
one unit. he reduction was however rejected in the cases of heterozygous copy neutral calls (CN2 LOH0), copy 
losses (CN1) and homozygous deletions (CN0). hese states were not altered.
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Due to heterogeneity, the gene expression values obtained did not represent the expression of the CN-altered 
cells solely. For each genomic region, a non-negligible proportion of cells do not harbour any alteration. he 
proportion of cells with normal heterozygous copy number in each region was estimated. When investigating 
the correlation between SCNAs and mRNA expression the weighted mean CN and LOH values of this mixture 
were used.
Ǥ Targeted enrichment and sequencing were performed on 1–3 µg of DNA extracted 
from the cell lines. Enrichment was performed using the SureSelect Human All Exon 50 MB v4 Kit (Agilent, 
Santa Clara, CA, USA) for the Illumina system. Sequencing was carried out on a HiSeq 2500 sequencer (Illumina 
Inc, San Diego, CA, USA), following the manufacturer’s protocols.
Ǥ Targeted enrichment and sequencing were performed on 225 ng of DNA extracted 
from the cell lines. Enrichment was performed using a custom HaloPlex Kit (Agilent, Santa Clara, CA, USA) 
targeting 41 genes. Sequencing was undertaken on a MiSeq sequencer (Illumina Inc, San Diego, CA, USA), fol-
lowing the manufacturer’s protocols.
Sequence data analysis. Raw paired-end reads were trimmed using Trimmomatic v0.33 to a minimum 
length of 30 nucleotides. Illumina Truseq adapters were removed in palindrome mode. A minimum Phred quality 
score of 30 was required for the 3′ end. Single end reads as well as paired end reads that failed previous minimum 
quality controls were discarded. Individual read groups were aligned, using bwa v0.7.12 with default parameters, 
to the UCSC hg19 reference human genome from Illumina iGenomes web site. Trimming rates and insert length 
were controlled on each read group based on metrics reported by Trimmomatic, and Picard v1.128 respectively.
Aligned reads from multiple read groups belonging to the same sample were indexed, sorted and merged 
using sambamba v0.5.4. Ampliication duplicates were removed using Picard.
Various quality controls parameters were used including the obtained target coverage of the Nextera Rapid 
Capture exome library v1.2, mapping rates and duplication rates, based on metrics collected for each sample 
using Samtools v1.2, Picard v1.141, bedtools v2.25.0, and aggregated using custom Python v2.7.9 codes.
We applied GATK v3.5.0 base quality score recalibration and indel realignment14 with standard parameters. 
We performed SNP and INDEL discovery and genotyping across each cohort of samples simultaneously using 
standard hard iltering parameters according to GATK Best Practices recommendations.
All variants were annotated with functional prediction using SnpEf v4.2. Additionally, functional annotation 
of variants found in two public databases (NCBI dbSNP v144 and dbNSFP v2.9) was added using SnpSit, part of 
the same sotware package. Multiallelic variants were decomposed and normalized using vt. A GEMINI v0.18.3; a 
database was created15, and variants selected according to functional rules. Finally, they were manually validated 
against read alignments, using Integrative Genomics Viewer sotware (IGV) v2.3. Coverage metrics were calcu-
lated using bedtools.
Variant filtering and mutation landscape plots. Variant filtering and mutation landscape 
plots. Variants with ExAC (non TCGA) population alternate allele frequency of 0.5% and above were removed 
from the VCFs created in the HaplotypeCaller analysis. Further probable germline variants were removed if they 
were labeled as germline in ClinVar database or if present in dbSNP, except if labeled as pathogenic in ClinVar or 
if present in COSMIC. he inal resulting VCFs were then converted to MAFs using vcf2maf v1.6.16. Variants that 
were non-coding or silent were removed, as those found in more than two samples, unless they were found only 
in the exome and HaloPlex capture of a same sample. Finally, to remove other potential rare germline variants 
or artefacts, we removed variants that were found in genes labeled as “High” in the “all cancer disease-causing 
genes” of the gene damage index (GDI)48, unless these were known HNSCC mutational cancer drivers according 
to IntOGen49,50. Mutation landscape plots were then created using the waterfall function in GenVisR51.
In total, 461 689 variants were detected in the 9 exome captures and 5337 variants in the 17 HaloPlex captures. 
Removing variants that had a population alternate allele frequency of 0.5% in the ExAC (non TCGA) database as 
well as additional germline iltering (described in Materials and Methods) gave 56 520 and 1189 variants. Keeping 
only coding variants with CADD scores of at least 10, that were found in a maximum of 2 samples brought these 
numbers down to 6436 and 68. However, a number of these were in genes known to cause a high amount of 
false positive somatic variants. hus, we removed variants in genes that were labeled as “High” in the “all cancer 
disease-causing genes” of the gene damage index (GDI)48, unless these were known HNSCC mutational cancer 
drivers according to IntOGen49,50. his led to a inal number of variants of 5766 for the exome captures and 59 for 
the HaloPlex captures.
Data Availability
he data for this study is available through Dryad Digitial Repository (https://doi.org/10.5061/dryad.314k5k5).
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